-
Gluetacs Therapeutics Files IND for Molecular Glue Degrading Agent in China
•
Gluetacs Therapeutics has reported filing an Investigational New Drug (IND) application for its first molecular glue degrading agent with the Center for Drug Evaluation in China. The company, which specializes in the development of small molecule drugs via protein degradation technology, has also secured an undisclosed amount of investment from…
-
Global Cord Blood Corporation Appoints Liquidators Amid Shareholder Dispute
•
Global Cord Blood Corporation (OTCMKTS: CORBF) has announced that the Grand Court of the Cayman Islands has appointed provisional liquidators and suspended the powers of the company’s directors. This follows a compulsory winding-up petition filed by GCBC’s majority shareholder, Blue Ocean Structure Investment Co., Ltd. As a result of the…
-
Ubrigene Raises Hundreds of Millions in Series C Financing Round
•
Yiming (Beijing) Cell Biotechnology Co., Ltd, also known as Ubrigene, a gene and cell therapy contract development and manufacturing organization (CDMO) founded in Beijing in 2015, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round. The round was led by Goldstone Investment and CLSA Capital,…
-
ThunderBio Secures Funding from Guangzhou LBP for PCR Innovation
•
ThunderBio Innovation Limited, a specialist in droplet microfluidics and molecular diagnostics based in Zhejiang, has raised an undisclosed amount of funding from Guangzhou LBP Medicine Science & Technology Co., Ltd. The collaboration will focus on advancing digital polymerase chain reaction (PCR) technology, including product research and development (R&D), manufacturing, and…
-
F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review
•
UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that the deadline for its proposed takeover by Sino Biopharmaceutical Ltd (HKG: 1177) subsidiary invoX Pharma has been delayed for a second time. The delay is attributed to a review by the Committee on Foreign Investment…
-
Shenzhen NeuroPlus Secures Seed Funding for Neuromodulation and Bioelectronic Medicine
•
Shenzhen NeuroPlus has reportedly raised “tens of millions” of renminbi in a seed financing round solely led by Brain Venture Capital. The proceeds will be directed towards medical device research and development, pre-clinical studies, and clinical trial filings. The Guangming Brain Science Technology Industry Innovation Center will provide NeuroPlus with…
-
Kamari Pharma Completes $8M Investment from Chinese Fund GIBF2
•
Israel-based Kamari Pharma has announced the completion of an $8 million investment from the Chinese fund GIBF2. This brings the total funds raised by Kamari to $16 million. The company was established at the end of 2018 by leading Israel-based biotech funds Pontifax and Arkin Bioholdings. Kamari develops topical and…
-
Koutech Robotics Secures Series A Funding for Surgical Innovation
•
China-based Koutech Robotics (Shanghai) Co., Ltd, a leading ultra-micro, high-precision surgical robot platform company, has reportedly raised “hundreds of millions” of renminbi in a Series A financing round. The round was led by Qiming Venture Partners, with contributions from Proxima Ventures, DNE Capital, Lingang Blue Bay Fund, Winfast Holding, and…
-
Suzhou Weiyou Gene Bio Raises Pre-Series A Funding for Gene Therapy Pipeline
•
China-based Suzhou View Gene Biotechnology Co., Ltd has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. The round was led by Proxima Ventures, with proceeds directed towards clinical studies, new adeno-associated virus (AAV) carrier design, pilot-scale production line construction, and expansion of the gene therapy…
-
Lepu Medtech Prices GDR Offering for International Expansion
•
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has priced its offering of 11,910,286 global depository receipts (GDRs) to the SWX Swiss Exchange (SWX) at USD 12.31 to USD 12.68 per share. The proceeds from the offering are expected to range from USD 148.8 million…
-
Zhong’ao Biopharmaceutical Secures Series A Funding for Cancer and HPV-Related Disease R&D
•
China-based Zhong’ao Biopharmaceutical Technology (Guangdong) Co., Ltd. has reportedly raised an undisclosed amount of money in a Series A financing round. The investment was led by Huaying Capital from Zhongshan Torch Development Zone and Chengdu Shengrong Longke Technology Co., Ltd. The funding will support the company’s ongoing research and development…
-
Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing
•
Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company (SPAC) Maxpro Capital Acquisition Corp., paving the way for a public listing on the Nasdaq stock exchange. The transaction values Apollomics at a pre-money equity of $899 million, with the company expecting to retain up…
-
Shenzhen Vivolight Raises RMB 100 Million in Series D1 Financing for Laser Therapy Development
•
China-based laser diagnosis and treatment specialist Shenzhen Vivolight Medical Device & Technology Co., Ltd reportedly raised over RMB 100 million (USD 14.2 million) in a Series D1 financing round. The round was led by Huajin Capital and Fosun Health Fund, with participation from Kaihe Capital, Sequoia China, and CASSTAR. The…
-
US Blocks Asymchem’s Acquisition of Snapdragon Chemistry
•
US authorities have intervened to block the purchase of US-based Contract Development and Manufacturing Organization (CDMO) Snapdragon Chemistry by China-based CDMO Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821). According to a press release from Snapdragon, the deal faced opposition from the US Treasury’s Committee on Foreign Investment in the United…
-
Suzhou Jade Biomedical Secures USD 10 Million Series B Financing
•
China-based Suzhou Jade Biomedical Co., Ltd reportedly raised USD 10 million in a Series B financing round led by VMS Group, with participation from Panacea Venture. The proceeds will be used for the purchase of instruments, reagents, and consumables for the company’s biological GMP testing business. Additionally, the funds will…
-
Worg Pharmaceuticals Raises RMB 400 Million in Series B Funding
•
Worg Pharmaceuticals, a Hangzhou-based developer of novel allergic drugs, reportedly raised RMB 400 million (USD 57.3 million) in a Series B financing round. This follows an RMB 200 million (USD 28.65 million) Series A funding round in January last year. The latest round was backed by Junson Capital, Lapam Capital,…
-
Bide Pharmatech Set for IPO on Shanghai’s STAR Market
•
Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make an initial public offering (IPO) of 16 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR), raising an estimated RMB 43.44 million (USD 6.2 million). The move marks a significant milestone for the…
-
Vathin Medical Instrument Raises Pre-Series B Funding Led by IDG Capital
•
China-based single-use bronchoscope specialist Hunan Vathin Medical Instrument Co., Ltd reportedly raised “hundreds of millions” of renminbi in a Pre-Series B financing round led by IDG Capital. Other investors included Founder Securities and Hunan Xiangtan Caixin Chanxing Equity Investment Partnership. The proceeds will be used to ramp up the company’s…
-
Leadinno Medical Valley Raises RMB 100M in Series A Financing for Neuromodulation Devices
•
Beijing-based neuromodulation medical device maker Leadinno Medical Valley reportedly raised over RMB 100 million (USD 14.4 million) in a Series A financing round led by Proxima Ventures and Med-Fine Capital. Other investors included TigerYeah Capital, Maron Investment, and Cowin Capital. The proceeds will be used for research and development (R&D)…
-
Suzhou InnoBM Pharmaceuticals Raises Series A+ Funding for Tumor Immunotherapy
•
China-based Suzhou InnoBM Pharmaceuticals reportedly raised tens of millions of renminbi in a Series A+ financing round led by Yuanbio Venture Capital. The proceeds will be used to advance clinical studies for tumor immunotherapies and develop pipeline candidates based on its unique biomaterial technology platform. Company BackgroundFounded in 2019, InnoBM…
